Amsbio, Abingdon, UK, has extended its covid-19 research portfolio with the introduction of a service to provide custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 to help researchers identify potential targets for development of therapeutic drugs and vaccines.
Various research groups around the world have demonstrated that SARS-CoV-2 uses its spike glycoprotein S, a main target for neutralization antibody, to bind its receptor and mediate membrane fusion and virus entry.
In response to widespread demand, Amsbio has developed a custom service to provide ready-to-use in vitro and in vivo grade lentiviral particles pseudotyped with the coronavirus S protein. Pseudotyping of lentivirus is available with wild type or mutant S proteins from a wide range of coronavirus species. In addition, Amsbio can offer wide-ranging customization options, including the addition of reporter genes for monitoring viral entry. This complete line of products are safe to be used in BSL-2 labs.
For more information, visit Amsbio.